Evicenter
P&T meetings

Tovorafenib (DAY101)

RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

Also known as TAK-580
Regulatory submission
Not announced
Launch
Not announced
Last updated
155 sources

Product information and disease descriptionProduct description

Product information

150 evidence topics · 49 sources

Effect of Tovorafenib on quality measures
Product-specific effect on quality measures

No evidence found.

Quality measures for pediatric low-grade glioma or pediatric CNS tumor care that reference targeted therapy

No evidence found.